

Objectives: Compare the sexual function of women with and without FM.

Methods: Sexually active women aged between 19 and 65 years with and without medical diagnosis of FM in a single center, matched for age and menopausal status, were evaluated. The exclusion criteria were pregnancy and use of medications with urinary side effects (urinary loss or retention). In a single interview the participants signed the Informed Consent Form and answered questions about personal and gynecological data. The protocol The Sexual Quotient – Female Version (QS-F) was applied to assess sexual performance. We used for statistical analysis t test for independent variables and Mann-Whitney Test for the others.

Results: In this study, 126 women were evaluated with age of 43.73 ± 10.48 years. Most of the patients were married, representing 58.7%. A total of 50% participants had 1 or 2 children, 22.2% between 3 and 4 children and 27.8% had no children. Regarding the age of menarche and menopausal status, no differences were observed between groups ($p=0.70$ and $p=0.08$, respectively). The QS-F score revealed significantly lower scores for women with FM when compared to the healthy group ($p<0.001$). We observed the same results in the domains: Desire and Sexual Interest ($p<0.001$), Excitation Phase ($p=0.019$) and Satisfaction and Orgasm ($p<0.001$). Regarding the Pain and Comfort domain, no differences were observed between the groups ($p=0.307$). However, when they were questioned about dyspareunia in the physiotherapeutic evaluation, it was observed that 51.6% of FM patients reported pain in sexual act against only 26.6% of healthy women ($p=0.005$).

Conclusions: Women with FM performed poorly on QS-F general score and in most domains, except for pain and comfort. When they were questioned in the physiotherapeutic evaluation about dyspareunia, we observed that women with FM had more pain in sexual intercourse, which may occurred due to the way the question was asked. As consequence, women with FM report worse sexual performance, especially with regard to desire, arousal phase and orgasm rate.

References:

- [1] Wolfe, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. *Arthritis Care & Research*, v.2, n.5, pg. 600–610, 2010.
- [2] Rebecca G. Rogers, M.D. Sexual function in women with pelvic floor disorders. *Can Urol Assoc J*; v 7, n. 9–10, p. 199–201, 2013.

Acknowledgements: This study received funds from CAPES (Coordination for the Improvement of Higher Education Personnel - Government Research Agency) with scholarship to one of the co-authors.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6293

THU0477 DOES FIBROMYALGIA AFFECT PHYSICAL ACTIVITY OF THE PATIENTS?

M. Alkan Melikoglu¹, S. Dogantekin². ¹Rheumatology, ATATURK UNIVERSITY FACULTY OF MEDICINE, Rheumatology; ²Physical medicine and Rehabilitation, ATATURK UNIVERSITY FACULTY OF MEDICINE, Erzurum, Turkey

Background: Fibromyalgia syndrome (FMS) as a chronic pain condition can cause impaired physical activity level of the patients.

Objectives: The purpose of this case-control study was to evaluate the physical activity levels of patients with FMS and to assess a possible relation between physical activity and disease characteristics.

Methods: Seventy patients with FMS and 50 age-gender matched controls were included in the study. The demographic features and duration of symptoms of the participants were recorded. The level of pain was evaluated using the visual analogue scale (VAS). The Fibromyalgia Impact Questionnaire (FIQ) scoring system was used for the evaluation of the impact of FMS. Also for assessing the physical activity in our participants, we used The International Physical Activity Questionnaire (IPAQ). Mann-Whitney U and Pearson correlation tests were used for group comparisons and was used for correlation analyses.

Results: The mean age of the patients and healthy controls were 41.90 ± 8.53 years and 41.52 ± 9.01 years, respectively. Symptom duration of the patients was 61.0 ± 45.8 months. The patients with FMS presented significantly less transportation-related, recreational and total physical activity levels, besides reporting significantly less time spent walking and less time spent in vigorous activities than healthy controls ($p<0.05$). Also, in patients with FMS, there was a negative correlation between pain and the scores of self-reported moderate or vigorous physical activity ($r = -0.41$, $p<0.01$). However, we couldn't find any correlation between FIQ and IPAQ scores.

Conclusions: Patients with FMS are physically less active than healthy individuals of similar profile. This reduced activity seems to be associated with pain, but not with the impact of the disorder. In the approach to the patient with FMS, considering the patient's physical activity behavior can contribute to the management of the disorder. In future studies assessing the effect of exercise in FMS, consideration of the patients' physical activity level may contribute to a complete evaluation of the patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3092

THU0478 DETERMINATION OF COMORBIDITIES IN FIBROMYALGIA SYNDROME

U. Bilge¹, T. Kaşifoğlu², N.S. Yaşar Bilge², H. Balcıoğlu¹, Y.E. Sarı¹, M. Kayhan¹, I. Ünlüoğlu¹. ¹Eskişehir Osmangazi University Faculty of Medicine Department of Family Medicine, Eskişehir Osmangazi University Faculty of Medicine Department of Family Medicine; ²Eskişehir Osmangazi University, Eskişehir Osmangazi University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Eskişehir, Turkey

Background: Although fibromyalgia syndrome is diagnosed by excluding other possible diagnosis based on the patient's clinical features, in recent the studies, it was shown that comorbid diseases affect the course of fibromyalgia.

Objectives: The aim of this study is to evaluate the comorbid diseases of patients with fibromyalgia and to determine the rates of comorbid diseases

Methods: In this study, age, gender and comorbid diseases of patients above 18 years and diagnosed with fibromyalgia by a were evaluated in the database system of the hospital retrospectively.

Results: A total of 509 patients were examined in our study. 51 of the patients were male, 458 were female (mean age was 50.24 ± 12.32). Of the patients, 345 (67.8%) had at least one comorbid disease while 164 (32.2%) had no comorbid disease. In the study, 187 of the patients (36.7%) had cardiovascular diseases, 157 of the patients (30.8%) had endocrine diseases, 63 of the patients (12.4%) had rheumatologic diseases, 30 of the patients (5.9%) had neurological diseases, 14 of the patients (2.8%) had other autoimmune diseases, 10 of the patients (2.0%) had cancers, 129 of the patients (25.3%) had mental disorders, 45 of the patients (8.8%) had chronic lung diseases, 37 of the patients (7.3%) had osteoporosis, 11 of the patients (2.2%) had other diseases (chronic pancreatitis, chronic renal failure, nephrotic syndrome, deep vein thrombosis, hepatitis serology positivity, pulmonary thromboembolism, organ transplantation).

Conclusions: FMS is an important disease that is increasing in frequency in recent years. FMS, which can be seen with many diseases, is in fact related to physicians from many branches, and it is useful to evaluate FMS patients with their comorbid conditions on their follow-up.

References:

- [1] Choy EH & Mease PJ. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). *Rheumatic Disease Clinics of North America*, 2009; 35(2):329–337.
- [2] Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis & Rheumatism*, 1990; 33(2):160–172.
- [3] Soran N, Altındağ Ö, Demirkol A, Sallı A, Yılmaz H, Kocabaş H, et al. Depression level and relation with clinical parameters in fibromyalgia syndrome. *Rheumatism*, 2008; 23:1–4.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5877

THU0479 THE PREVALENCE OF XEROSTOMIA IN PATIENS WITH FIBROMYALGIA

N.M. Lloves Schenone, A. Secco, V. Durigan, S. Scarafia, F.E. Romanini, M. Mamani. *Servicio de Reumatología, Hospital Bernardino Rivadavia, Buenos Aires, Argentina*

Background: Fibromyalgia (FM) is a rheumatic disease characterized by diffuse, chronic musculoskeletal pain, of non-articular origin, which is evidenced by the palpation of painful points in specific anatomical areas and is usually accompanied by non-repairing sleep, Tiredness, morning stiffness, cognitive alterations, among others.

FM affects approximately 0.5 -5% of the population, having a maximum prevalence between 40 and 50 years. No racial or socioeconomic predisposition has been determined to date.

Sicca syndrome whose term encompasses xerophthalmia, xerostomia, xeroderma and xerovagina, has been described in patients with FM. Xerostomia is the sensation of dry mouth due to lack or decrease of saliva. There are no clinical studies that determine the prevalence of xerostomia in patients with FM and on the other hand the reduction of salivary flow in these patients has not been studied with objective tests.

Objectives: The aim of this study was to determine the frequency of xerostomia in patients with diagnosis of Fibromyalgia and describe their clinical and epidemiologic characteristics.

Methods: Patients were included according 1990 and 2010 ACR Classification criteria. Patients taking drugs that cause xerostomia were excluded as well as the ones presenting other rheumatologic diseases. Xerostomia was assessed by interrogation and physical examination, and a sialometry was performed in order to determine the decrease of salivary flow. A sialometry was positive if the saliva flow was under 1.5 ml in 15 minutes. In case of presenting positive sialometry patients were studied to rule out Sjogren Syndrome with laboratory and minor salivary gland biopsy.

Results: 50 patients were recruited during the study. The 100% of them were women. The mean age was 47 years old ($DS=8.5$), while the mean time of evolution of FM was 6 years. 29 patients reported xerostomia of which 4 presented positive sialometry. No positive sialometry was found in the group that did not referred xerostomia. Smoking was more prevalent in patients with FM who did not